Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

XLO stock hub

Xilio Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

XLOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

46.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

XLO

In the news

Latest news · XLO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-132.5

P25 -105.6P50 -46.5P75 -3.1

ROIC-77.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All XLO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001840233
Company name	Xilio Therapeutics, Inc.
Country	United States
Country code	US
Cusip	98422T209
Employees	76
Employees Change	12%
Employees Change Percent	18.75
Enterprise value	$-84.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-10-22
Isin	US98422T2096
Last refreshed	2026-05-10
Market cap	$46.3M
Market cap category	Nano-Cap
Price	$7.74
Price currency	USD
Rev Per Employee	575,868.42x
Sector	Healthcare
Sic	2834
Symbol	XLO
Website	https://xiliotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-75.66%
FCF yield	-11.9%
P/B ratio	0.99x
P/S ratio	1.06x
PS Forward	1.68x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-95.92%
EBITDA Margin	-92.4%
Gross margin	100%
Gross Profit	$43.8M
Gross Profit Growth	589.88%
Gross Profit Growth Q	51.33%
Net Income	$-35M
Net Income Growth Quarters	1%
Net Income Growth Years	3%
Pretax Margin	-80.05%
Profit Margin	-80.05%
Profit Per Employee	$-461,000
ROA	-23.24
Roa5y	-39.45
ROCE	-42.66
ROE	-132.5
Roe5y	-119.7
ROIC	-77.21

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-17.06%
Cagr3y	-43.82%
EPS Growth Quarters	11
EPS Growth Years	5
Revenue Growth	589.88x
Revenue Growth Q	693.85x
Revenue Growth Quarters	3x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.39
Assets	$154.7M
Cash	$137.5M
Current Assets	$145M
Current Liabilities	$56.3M
Debt	$7M
Debt Equity	$0.2
Equity	$35.3M
Liabilities	$119.4M
Long Term Assets	$9.7M
Long Term Liabilities	$63.1M
Net Cash	$130.6M
Net Cash By Market Cap	$282
Net Cash Growth	176.95%
Net Debt Equity	$-3.7
Tangible Book Value	$35.3M
Tangible Book Value Per Share	$7.79
WACC	3.07

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.58
Net Working Capital	$-47.4M
Quick ratio	2.53
Working Capital	$88.8M
Working Capital Turnover	$0.72

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-18.53%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-17.05%
200-day SMA	9.38
3Y total return	-82.28%
50-day SMA	8.05
50-day SMA vs 200-day SMA	50under200
All Time High	391.3
All Time High Change	-98.02%
All Time High Date	2021-11-16
All Time Low	6.47
All Time Low Change	19.72%
All Time Low Date	2026-03-12
ATR	0.48
Beta	-0.13
Beta1y	0.58
Beta2y	0.23
Ch YTD	-13.64
High	7.91
High52	16.52
High52 Date	2025-05-13
High52ch	-53.15%
Low	7.6
Low52	6.47
Low52 Date	2026-03-12
Low52ch	19.72%
Ma50ch	-3.86%
Price vs 200-day SMA	-17.52%
RSI	41.33
RSI Monthly	29.26
RSI Weekly	39.94
Sharpe ratio	0.15x
Sortino ratio	0.32
Total Return	-18.53%
Tr YTD	-13.64
Tr1m	-8.94%
Tr1w	-6.97%
Tr3m	2.21%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	1
Analyst Ratings	Buy
Earnings EPS Estimate	$-0.66
Earnings Revenue Estimate	8,520,000x
Earnings Revenue Estimate Growth	190.78x
Operating Income	$-42M
Operating margin	-95.92
Price target	$28
Price Target Change	$262

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,646,738%
Float Percent	60.95%
Shares Insiders	8.99%
Shares Institutions	20.66%
Shares Out	5,982,839
Shares Qo Q	22.38%
Shares Yo Y	18.53%
Short Float	4.78%
Short Ratio	3.82
Short Shares	2.91

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-12.4M
Average Volume	33,061.65x
Bv Per Share	7.79
CAPEX	$-518,000
Ch1m	-8.94
Ch1w	-6.97
Ch1y	-17.05
Ch3m	2.21
Ch3y	-82.28
Ch6m	-31.49
Change	-0.9%
Change From Open	-0.13
Close	7.81
Days Gap	-0.77
Depreciation Amortization	1,541,000
Dollar Volume	177,602
Earnings Date	2026-05-14
Earnings Time	bmo
EBIT	$-42M
EBITDA	$-40.4M
EPS	$-7.73
F Score	3
FCF	$-5.5M
FCF EV Yield	6.54x
FCF Per Share	$-0.92
Financing CF	87,775,000
Fiscal Year End	December
Founded	2,016
Investing CF	-518,000
Ipr	-51.63
Iprfo	-96.31
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-23
Last Report Date	2025-12-31
Last Split Date	2026-03-16
Last Split Type	Reverse
Last10k Filing Date	2026-03-23
Ma150	9.15
Ma150ch	-15.45%
Ma20	8.22
Ma20ch	-5.81%
Net CF	82,265,000
Next Earnings Date	2026-05-22
Open	7.75
Optionable	No
Position In Range	45.16
Post Close	7.74
Postmarket Change Percent	3.75
Postmarket Price	$8.03
Ppne	7,851,000
Price Date	2026-05-08
Ptbv Ratio	1.31
Relative Volume	0.69x
Revenue	43,766,000x
SBC By Revenue	15.85x
Share Based Comp	6,939,000
Tr6m	-31.49%
Us State	Massachusetts
Volume	22,946
Z Score	-3.52

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does XLO pay a dividend?

Capital-return profile for this ticker.

Performance

XLO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns XLO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+20.7%

Float: +61.0% of shares outstanding

Insider ownership

+9.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

XLO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.3

Neutral momentum band

Price vs 200-day MA

-17.5%

50/200-day relationship not available

Beta (5Y)

-0.13

Less volatile than the market

Sharpe ratio

0.15

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About XLO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current XLO stock rating?

Xilio Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full XLO analysis?

The full report lives at /stocks/XLO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for XLO?

The latest report frames XLO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the XLO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.